Lupin has launched Tadalafil Tablets USP 20mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. The company’s Tadalafil Tablets USP 20mg is the generic equivalent of Eli Lilly's Adcirca Tablets 20mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil Tablets, 20mg (RLD: Adcirca) had annual sales of approximately $474.3 million in the US (IQVIA MAT December 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
